LLY

983.75

+0.69%↑

JNJ

241.8

-0.66%↓

ABBV

219.65

-2.66%↓

NVS

153.23

-0.58%↓

AZN

189.72

-1.14%↓

LLY

983.75

+0.69%↑

JNJ

241.8

-0.66%↓

ABBV

219.65

-2.66%↓

NVS

153.23

-0.58%↓

AZN

189.72

-1.14%↓

LLY

983.75

+0.69%↑

JNJ

241.8

-0.66%↓

ABBV

219.65

-2.66%↓

NVS

153.23

-0.58%↓

AZN

189.72

-1.14%↓

LLY

983.75

+0.69%↑

JNJ

241.8

-0.66%↓

ABBV

219.65

-2.66%↓

NVS

153.23

-0.58%↓

AZN

189.72

-1.14%↓

LLY

983.75

+0.69%↑

JNJ

241.8

-0.66%↓

ABBV

219.65

-2.66%↓

NVS

153.23

-0.58%↓

AZN

189.72

-1.14%↓

Search

Medtronic PLC

Suletud

SektorTervishoid

87.07 -0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

86.71

Max

88.52

Põhinäitajad

By Trading Economics

Sissetulek

-231M

1.1B

Müük

57M

9B

P/E

Sektori keskmine

25.514

61.417

Aktsiakasum

1.36

Dividenditootlus

3.11

Kasumimarginaal

12.675

Töötajad

95,000

EBITDA

124M

2.5B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+28.22% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.11%

2.40%

Järgmine tulemuste avaldamine

20. mai 2026

Järgmine dividendimakse kuupäev

17. apr 2026

Järgmine aktsia dividendi kuupäev (ex-date)

27. märts 2026

Turustatistika

By TradingEconomics

Turukapital

-10B

117B

Eelmine avamishind

87.58

Eelmine sulgemishind

87.07

Uudiste sentiment

By Acuity

34%

66%

86 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Medtronic PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2026, 11:19 UTC

Omandamised, ülevõtmised, äriostud

Medtronic to Buy Scientia Vascular in $550 Million Deal

17. veebr 2026, 12:43 UTC

Tulu

Medtronic 3Q Profit Falls Despite Higher Revenue

3. veebr 2026, 13:53 UTC

Omandamised, ülevõtmised, äriostud

Medtronic to Acquire CathWorks in Deal Valued Up to $585 Million

10. märts 2026, 10:46 UTC

Omandamised, ülevõtmised, äriostud

Medtronic: Scientia Deal Complements Neurovascular Portfolio >MDT

10. märts 2026, 10:46 UTC

Omandamised, ülevõtmised, äriostud

Medtronic: Scientia Deal Includes Potential Undisclosed Earn-Out, Milestone Payments >MDT

10. märts 2026, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Medtronic: Scientia Vascular Acquisition Valued at $550 Million >MDT

10. märts 2026, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Medtronic to Acquire Scientia Vascular >MDT

17. veebr 2026, 21:21 UTC

Tulu

These Stocks Are Today's Movers: Paramount, Masimo, Medtronic, Kyndryl, eToro, Genuine Parts, Southwest, and More -- Barrons.com

17. veebr 2026, 18:11 UTC

Tulu

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17. veebr 2026, 14:48 UTC

Tulu

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17. veebr 2026, 13:00 UTC

Tulu

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17. veebr 2026, 12:05 UTC

Tulu

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17. veebr 2026, 11:47 UTC

Tulu

Medtronic Sees 2026 EPS up 4.5%, Excluding Potential Impact From Tariffs >MDT

17. veebr 2026, 11:47 UTC

Tulu

Medtronic Still Sees FY26 Organic Revenue Up About 5.5% >MDT

17. veebr 2026, 11:46 UTC

Tulu

Medtronic FY26 View Includes Potential Impact From Tariffs of About $185M >MDT

17. veebr 2026, 11:46 UTC

Tulu

Medtronic Backs FY26 View of Adj EPS $5.62-Adj EPS $5.66 >MDT

17. veebr 2026, 11:46 UTC

Tulu

Medtronic Reiterates FY26 Organic Rev Growth, EPS Guidance >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Adj EPS $1.36 >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Neuroscience Portfolio Rev $2.56B >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Organic Revenue Up 6.0% >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Sales $9.02B >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Diabetes Rev $796M >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Cardiovascular Portfolio Rev $3.46B >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Medical Surgical Portfolio Rev $2.17B >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q Net $1.14B >MDT

17. veebr 2026, 11:45 UTC

Tulu

Medtronic 3Q EPS 89c >MDT

17. veebr 2026, 09:53 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Norwegian, Hyatt, Zim, Medtronic -- WSJ

3. veebr 2026, 13:38 UTC

Omandamised, ülevõtmised, äriostud

Medtronic to Acquire CathWorks in Deal Valued Up to $585M

3. veebr 2026, 13:21 UTC

Omandamised, ülevõtmised, äriostud

Medtronic Sees Deal Neutral to Accretive Thereafter >MDT

3. veebr 2026, 13:21 UTC

Omandamised, ülevõtmised, äriostud

Medtronic: Acquisition Is Expected to Be Immaterial to FY27 GAAP and Adj EPS >MDT

Võrdlus sarnastega

Hinnamuutus

Medtronic PLC Prognoos

Hinnasiht

By TipRanks

28.22% tõus

12 kuu keskmine prognoos

Keskmine 114.08 USD  28.22%

Kõrge 125 USD

Madal 100 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Medtronic PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

11

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

83.26 / 84.875Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

86 / 351 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
help-icon Live chat